ARCHIVES

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

This article is from The Cancer Letter archive.

Vol. 21 No. 43 | November 10, 1995

Download PDF Visit The Full Archive

Related Articles

Also R01 payline likely to fall below 20th percentile in FY04.

September 26, 2003

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

July 27, 2001

MAP Says It Will Continue Operating With Private Funds

April 18, 1986

New Community Center Assnt. Determined To Improve Quality Of Care “With Or Without” NCI Assistance

September 27, 1974

Immunotherapy Shrinks Tumors In Phase I Study at St. Jude

May 30, 2014

Interview with Mark Ratain: Too Much Emphasis On Precision, Not Enough Emphasis On Accuracy In Dosing

October 8, 2010